title: Efficacy of propranolol for cutaneous hemangiomas in premature children.
abstract: BACKGROUND
  The purpose of the present study is to evaluate the efficacy and safety of propranolol for problematic infantile hemangiomas (IH), showing our experience on 24 children, with special focus on premature infants.
  
  
  METHODS
  A retrospective observational study considered 24 patients who were given oral propranolol for the treatment of "problematic" IH. A multidisciplinary team, composed of a dermatologist, a pediatrician, a pediatric cardiologist, and a neonatologist, took part in the indication for propranolol and follow-up on all the patients. Propranolol was administered orally at the starting dose of 0.5-1 mg/kg/die and was gradually increased to the target dose of 2 mg/kg/die. A clinical gravity score, based on color, major diameter, thickness and texture was calculated for each IH, giving a numeric score before (t0) and after (tf) propranolol therapy. Improvement rate was evaluated in terms of score percentage difference between t0 and tf.
  
  
  RESULTS
  All of the IH except one (96%), showed a variable grade of improvement, with a median score improvement of 69.1%. Median initial score in premature and term infants did not show any significant difference (P=0.38). Otherwise the two subgroups showed a significant difference in final scores: medium percentage improvement in premature and term infants, was respectively 80.9% and 49.6% (P<0.01). No significant side effects were reported during the treatment period.
  
  
  CONCLUSIONS
  As pointed out in our study, IH in premature children showed a significantly better response to propranolol treatment.
authors.affiliation: Institute of Dermatology, Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, San Matteo Polyclinic and Scientific Research Foundation, University of Pavia, Pavia, Italy - v.brazzelli@smatteo.pv.it.
authors.forename: Valeria
authors.initials: V
authors.lastname: Brazzelli
authors.forename: Chiara
authors.initials: C
authors.lastname: Giorgini
authors.forename: Stefania
authors.initials: S
authors.lastname: Barruscotti
authors.forename: Claudia A
authors.initials: CA
authors.lastname: Codazzi
authors.forename: Savina
authors.initials: S
authors.lastname: Mannarino
authors.forename: Chryssoula
authors.initials: C
authors.lastname: Tzialla
authors.forename: Mauro
authors.initials: M
authors.lastname: Stronati
authors.forename: Gian L
authors.initials: GL
authors.lastname: Marseglia
authors.forename: Giovanni
authors.initials: G
authors.lastname: Borroni
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006391:Hemangioma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008297:Male; D010348:Patient Care Team / Q000458:organization & administration; D011433:Propranolol / Q000008:administration & dosage* / Q000009:adverse effects; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D011433:Propranolol